Galapagos NV ADR

$24.66
(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Galapagos NV ADR

Stock Price
$24.66
Ticker Symbol
GLPG
Exchange
NASDAQ

Industry Information for Galapagos NV ADR

Sector
Healthcare
Industry
Biotechnology

Company Description for Galapagos NV ADR

Website
https://www.glpg.com
Country
USA
Full Time Employees
704

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Fundamentals for Galapagos NV ADR

Market Capitalization
$1,625,022,464
EBITDA
$-153,319,008
Dividends per Share
P/E Ratio
Forward P/E Ratio
166.67
Earnings per Share
$-0.02
Earnings per Share Estimate Next Year
Profit Margin
26.88%
Shares Outstanding
65,897,100
Percent Owned by Insiders
0.00%
Percent Owned by Institutions
48.13%
52-Week High
52-Week Low

Technical Indicators for Galapagos NV ADR

50-Day Moving Average
200-Day Moving Average
RSI
49.59
ATR
0.76

Analyst Ratings for Galapagos NV ADR

Strong Buy
1
Buy
0
Hold
6
Sell
1
Strong Sell
0

News About Galapagos NV ADR

Apr 15, 2025, 1:30 AM EST
Galapagos NV See more.
Apr 11, 2025, 3:05 PM EST
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. See more.
Apr 1, 2025, 11:50 AM EST
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. See more.
Mar 27, 2025, 4:01 PM EST
Galapagos NV See more.